Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company dedicated to improving patient outcomes through its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Headquartered in Kansas City, Kansas, the company is focused on developing next-generation pharmaceutical products that address conditions requiring burdensome daily dosing regimens and that often yield suboptimal treatment outcomes.
Cingulate’s lead candidates target Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety disorders, with a particular emphasis on their flagship product, CTx-1301. CTx-1301 utilizes dexmethylphenidate, a compound approved by the FDA, to provide a rapid onset and entire active-day efficacy through three precisely timed medication releases. This approach aims to eliminate the need for booster doses and improve overall patient compliance and satisfaction. The product has already demonstrated significant promise in Phase 3 trials, with impressive clinical effect sizes that suggest broad potential impact.
Another key product in the pipeline is CTx-2103, a novel extended-release formulation of buspirone designed for the treatment of anxiety. CTx-2103 leverages the PTR platform to deliver three timed doses in one tablet, potentially offering substantial benefits over current multi-dose regimens. This product is currently progressing through clinical trials, with positive feedback from the FDA on its regulatory pathway.
In recent months, Cingulate has achieved several milestones: they announced successful Phase 3 trial data for CTx-1301, closed a $4 million public offering, and converted $5.8 million of debt into equity. These financial maneuvers have strengthened their balance sheet, enabling continued investment in their clinical programs. Additionally, Cingulate recently welcomed new executive leadership and independent directors, further fortifying their capabilities as they navigate the complexities of drug development and commercialization.
Cingulate is committed to ongoing research and development, leveraging its PTR platform not only for ADHD and anxiety but also exploring other therapeutic areas. This innovative platform integrates an Erosion Barrier Layer (EBL), which controls the drug release at precise times without premature release, enhancing the effectiveness and convenience of treatment.
For more information, visit their official website at Cingulate.com.
Cingulate Inc. (NASDAQ: CING) announced a Master Services Agreement (MSA) with Societal CDMO to enhance its manufacturing capabilities. Societal CDMO will produce clinical and commercial batches for CTx-1301, a leading candidate for treating ADHD, at its Gainesville, GA facility. This partnership is expected to streamline the production process as Cingulate prepares for a Phase 3 dose-optimization study for CTx-1301, set to start in December 2022. If successful, a New Drug Application (NDA) is planned for submission in early 2024.
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company, announced that Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022, at 10:00 a.m. PT. The event will take place at the Luxe Sunset Boulevard Hotel in Los Angeles, with live streaming available at this link. The company, utilizing its Precision Timed Release™ (PTR™) technology, focuses on developing next-generation pharmaceutical products for neurological disorders and other therapeutic areas.
Cingulate Inc. (NASDAQ: CING) announced findings from a formulation study for CTx-2103, a once-daily buspirone treatment for anxiety disorders, presented at the 2022 Psych Congress. The study demonstrated the ability of CTx-2103 to deliver a triple-release formulation, enhancing patient compliance and treatment outcomes. The CEO emphasized the importance of formulation development in achieving effective medications. CTx-2103 aims to provide benefits over existing treatments by eliminating the need for multiple daily doses.
Cingulate Inc. (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer will speak at the Benzinga All Access event on August 19, 2022, at 9 a.m. CST. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate’s Precision Timed Release™ (PTR™) platform into anxiety treatment. The event can be viewed live on Benzinga’s YouTube channel and on Cingulate’s investor website.
Cingulate is dedicated to improving treatment outcomes for patients through innovative drug delivery technology.
Cingulate Inc. (NASDAQ: CING) announced its Q2 financial results, highlighting a $5 million non-dilutive debt financing and the appointment of Scott Applebaum to its Board of Directors. As of June 30, 2022, Cingulate's cash and equivalents stood at $8.2 million. R&D expenses rose to $2.2 million, while G&A expenses increased to $1.9 million, leading to a net loss of $4 million for the quarter. The company plans to continue development of its ADHD treatment, CTx-1301, with a Phase 3 study expected to commence soon. Positive NDA filing anticipated by late 2023 requires additional capital of $16.5 million.
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, announced that its CFO, Lou Van Horn, was honored as a 2022 CFO of the Year by the Kansas City Business Journal. This is the second time Lou has received this accolade, recognizing his financial leadership and expertise. The award ceremony took place on July 22, 2022. Lou, who played a crucial role in Cingulate's IPO in 2021, expressed gratitude for the recognition and highlighted the positive economic outlook for the Kansas City region.
Cingulate Inc. has announced the completion of the formulation study for CTx-2103, a new once-daily treatment for anxiety-related disorders using its proprietary Precision Timed Release™ (PTR™) drug delivery technology. This study, conducted in the UK, aims to improve adherence by reducing the dosing frequency of the active ingredient, buspirone. Results are anticipated in August 2022. CTx-2103 is designed to offer significant advantages over existing medications while addressing a substantial market need, as anxiety disorders affect approximately 31% of U.S. adults at some point in their lives.
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on June 23, 2022, at 1:40 PM EST. Chairman and CEO, Shane J. Schaffer, PharmD, will lead the presentation and follow up with a Q&A session. Investors can register for the event and access live webcasts via the provided links. Cingulate focuses on its proprietary Precision Timed Release™ (PTR™) drug delivery technology for developing next-generation products, initially targeting ADHD.
Cingulate Inc. (NASDAQ: CING) has announced that its Chairman and CEO, Shane J. Schaffer, and scientific advisor, Dr. Ann Childress, will participate in a live event on June 3, 2022, at 8:45 a.m. CST, hosted by Benzinga. The discussion will focus on unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety treatments. This event can be accessed via Benzinga’s YouTube channel and Cingulate's website.
Cingulate Inc. (NASDAQ: CING) announced the completion of enrollment in a clinical study for CTx-2103, a novel buspirone formulation aimed at treating anxiety disorders. This study, initiated in May 2022 with 12 participants, is set to yield results in July 2022. CTx-2103 employs Cingulate's proprietary Precision Timed Release™ (PTR™) technology, enabling once-daily dosing. The formulation could address issues of nonadherence prevalent with current treatments, offering potential for improved patient outcomes in a significant $5.5B U.S. anxiety market.
FAQ
What is the current stock price of Cingulate (CING)?
What is the market cap of Cingulate (CING)?
What does Cingulate Inc. specialize in?
What is CTx-1301?
What recent financial achievements has Cingulate accomplished?
What is the Precision Timed Release™ (PTR™) platform?
How does CTx-2103 differ from other anxiety treatments?
What was the outcome of the Phase 3 trial for CTx-1301?
What is CTx-2103 being developed for?
What distinguishes Cingulate Inc. from other biopharmaceutical companies?
Where is Cingulate Inc. headquartered?
How can I learn more about Cingulate Inc.?
